Interferon gamma receptor complex (IFNGR) (IFNGR)

The Interferon gamma receptor complex (IFNGR) is a heterotetrameric cell-surface receptor composed of two ligand-binding IFNGR1 (alpha) subunits and two signal-transducing IFNGR2 (beta) subunits (UniProt: P15260, P38484). It serves as the primary mediator for Interferon-gamma (IFN-γ), a critical cytokine produced by T cells and natural killer cells that orchestrates the transition from innate to adaptive immunity. Upon binding IFN-γ, the complex activates the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, specifically involving JAK1, JAK2, and STAT1, which regulates the transcription of hundreds of interferon-stimulated genes (PubMed: 28807917). In oncology, the IFNGR complex on tumor cells and microenvironment cells plays a paradoxical role; while it is essential for anti-tumor immunity through MHC upregulation and Th1 polarization, chronic signaling can induce immune evasion by upregulating PD-L1 and other inhibitory molecules (PubMed: 30546054). Therapeutic strategies include the use of recombinant IFN-γ (Interferon gamma-1b) to enhance immune responses or the use of anti-IFN-γ antibodies (e.g., Emapalumab) and JAK inhibitors to treat hyper-inflammatory syndromes like hemophagocytic lymphohistiocytosis (FDA: Gamifant). Mutations or epigenetic silencing of the IFNGR subunits are frequently associated with primary and acquired resistance to immune checkpoint blockade therapies (PubMed: 27565344).

Other names

IFN-gamma receptorIFNGR1/IFNGR2 complexCD119Interferon gamma receptor 1Interferon gamma receptor 2IFNG receptor

Agonism of the receptor complex via recombinant interferon gamma to stimulate anti-tumor or anti-infective immune responses; Antagonism of the ligand or inhibition of downstream JAK/STAT signaling to reduce hyper-inflammation and immune-mediated pathology.